Sector News

FTC staff recommends approval of Roche deal for Spark: report

October 29, 2019
Life sciences

The Federal Trade Commission staff reviewing Roche’s plan to buy U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported on Thursday.

Basel-based Roche, the biggest maker of cancer drugs, said in February that it would buy the U.S. company, acquiring a portfolio that includes a blindness treatment that has U.S. and European approval and other projects for neurodegenerative disorders like Huntington’s disease. One of its projects is a gene therapy treatment for hemophilia.

The FTC staff had focused on hemophilia treatments since Roche markets Hemlibra, the report said.

Following the staff’s recommendation, officials at the top of the FTC’s Bureau of Competition must weigh in. The next step would be a vote by the FTC chairman and four commissioners.

The deal must also win approval from the UK’s Competition and Markets Authority, which said this week that it had a deadline of mid-December for a Phase 1 decision. A Phase 2 probe would be more in-depth and detailed.

Roche, Spark and the FTC all declined comment.

By Diane Bartz

Source: Reuters

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 23, 2021

Thermo Fisher Scientific acquires Novasep’s Henogen for $874.5m

Life sciences

Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash. Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.

January 23, 2021

Lilly and Merus partner to develop T-Cell re-directing antibody therapies

Life sciences

Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.

January 23, 2021

Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer

Life sciences

Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.

Send this to a friend